The annual meeting of the American Society of Clinical Oncology was held from May 29 to June 2 in Chicago and hosted participants from around the world, including clinicians, academicians, allied health professionals, and others interested in oncology. The conference featured the latest advances in clinical cancer research, including oral abstract presentations and poster presentations in disease-based and specialty tracks. Presentations focused on novel targeted therapies as well as improvements in chemotherapy and radiation therapy approaches.
“This year”s annual meeting hit an all-time attendance record. We had over 45,000 people registered, representing 129 countries. Amazing. It really felt very global. All five of the abstracts in the plenary session really will change standard of care, at least when the drugs become available in the U.S.,” Julie R. Gralow, M.D., the executive vice president and chief medical officer for the American Society of Clinical Oncology, told HealthDay. “The overwhelming most impressive big game changer was the RASolute 302 trial of daraxonrasib, the RAS inhibitor. And it got a standing ovation when the survival curves went up of multiple minutes. You know, probably the biggest advancement in the treatment of cancer in the past decade.”
ASCO: Daraxonrasib Effective for Metastatic Pancreatic Ductal Adenocarcinoma
MONDAY, June 1, 2026 (HealthDay News) — Daraxonrasib is effective for patients with RAS-mutant and other metastatic pancreatic ductal adenocarcinomas, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 29 to June 2 in Chicago.
ASCO: Tile-Based Radiation Beneficial for Newly Resectable Brain Mets
FRIDAY, June 5, 2026 (HealthDay News) — For patients with newly diagnosed resectable brain metastases, cesium-131 tile-based radiation therapy, which delivers focal radiation immediately upon resection, yields significantly better outcomes than postoperative stereotactic radiation, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 29 to June 2 in Chicago.
ASCO: Apalutamide + ADT Beneficial in High-Risk Localized Prostate Cancer
FRIDAY, June 5, 2026 (HealthDay News) — Perioperative treatment with apalutamide and androgen deprivation therapy is beneficial for patients with high-risk localized or locally advanced prostate cancer, according to a study published online June 2 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 29 to June 2 in Chicago.
ASCO: Lower Incidence of Breast Cancer Seen With GLP-1 Receptor Agonist Exposure
Tobacco Treatment Program Effective in Oncology Settings 
New Cancer Cases Predicted to Increase to 34.4 Million by 2050 
Odds of HPV-Related Cancers Up for People With HIV, Solid Organ Transplant Recipients .jpg)
Men More Likely to Be Diagnosed at Regional, Distant Cancer Staging 
Hematologic Cancer Survivors Face Higher Risk of Developing Cardiovascular Disease 
Cardiac Remodeling May Portend Cancer Risk 
Patient-, Clinician-Directed Nudges Increase Rates of Serious Illness Conversations in Oncology Setting 
